Aelis Farma S.A.
AELIS.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.10 | 0.49 | 0.01 | -1.66 |
| FCF Yield | -42.75% | -7.53% | -8.23% | 15.52% |
| EV / EBITDA | -2.26 | -23.97 | -8.00 | 121.53 |
| Quality | ||||
| ROIC | -46.80% | -37.28% | -35.15% | 5.46% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 1.55 | 2.48 | 0.91 | 33.05 |
| Growth | ||||
| Revenue 3-Year CAGR | -11.08% | -0.08% | 49.63% | 908.37% |
| Free Cash Flow Growth | 7.54% | 3.90% | -170.31% | 846.40% |
| Safety | ||||
| Net Debt / EBITDA | 0.92 | 2.55 | 1.88 | -21.68 |
| Interest Coverage | -37.55 | -41.15 | -76.12 | 18.23 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 335.56 | 76.72 | 131.19 | 64.80 |